Common Contracts
3 similar Collaborative Research Agreement contracts by Xenogen Corp
COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • May 3rd, 2004 • Xenogen Corp • Services-commercial physical & biological research • New Jersey
This COLLABORATIVE RESEARCH AGREEMENT (“Agreement”) is entered into as of September 30,2001 by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and XENOGEN BIOSCIENCES (“Xenogen Cranbury”), an Ohio Corporation, with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned subsidiary of Xenogen Corp. (“Xenogen”).
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • May 3rd, 2004 • Xenogen Corp • Services-commercial physical & biological research • New Jersey
This COLLABORATIVE RESEARCH AGREEMENT (“Agreement”) is entered into as of December 28, 2000 by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and XENOGEN BIOSCIENCES (“Xenogen Cranbury”), an Ohio Corporation, with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned subsidiary of Xenogen Corp. (“Xenogen”).
CONFIDENTIAL TREATMENT GRANTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND SEPARATELY FILED WITH THE COMMISSION.] COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • April 2nd, 2004 • Xenogen Corp • Services-commercial physical & biological research • New Jersey
This COLLABORATIVE RESEARCH AGREEMENT (“Agreement”) is entered into as of December 28, 2000 by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and XENOGEN BIOSCIENCES (“Xenogen Cranbury”), an Ohio Corporation, with an office at 5 Cedar Brook Drive, Cranbury, NJ 08512, and a wholly owned subsidiary of Xenogen Corp. (“Xenogen”).
